adherium

Company Snapshot

Founded: 2001
Entity Type: Public
Region: Europe
Revenue: $5.3 Millions
Revenue Year: 2024
Headquarter: Australia
Key Geographics: North America, Europe, New Zealand, Australia
Corporate Address: Collins Square, Tower Four Level  18, 727 Collins Street Melbourne VIC 3008 Australia Tel. +61-(650)-446-8589 www.adherium.com

Company Overview

Incorporated in 2001, Adherium designs, develops, manufactures and supplies digital health technologies for the management of chronic diseases. It offers Smartinhaler, a medical device for prescription respiratory medications. Nexus6 received FDA clearance for its smartphone-connected inhaler. The new SmartTouch device has been cleared as a prescribable metered dose inhaler with a limited number of clinical uses.

Financial Highlights (FY 2024)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

adherium In Reports

Smart Inhalers: Global Markets

BCC Research detailed report on smart inhalers market revenue estimates (in $million) for the base year 2024 and forecasts for the period 2025 through 2030.

Chronic Disease Management: Therapeutics, Device Technologies and Global Markets

BCC Research Market Report for Chronic Disease Management. Global Chronic Disease Management market trends, with CAGRs through 2026.

Medication Adherence: Systems, Technologies and Global Markets

According to BCC Research global market for medication adherence systems and technologies should grow from $3.5 billion in 2020 to $6.0 billion by 2025 with a compound annual growth rate (CAGR) of 11.4%.

Company's Business Segments

  • Digital Health Technologies : The company provides integrated digital health solutions and connected respiratory medical devices.

Applications/End User Industries

  • Healthcare
  • Digital Health
  • Medical Devices
  • Connected Medical Devices
AI Sentiment